The role of pharmacogenic factor in the modulation of compliance to treatment
https://doi.org/10.31363/2313-7053-2022-56-3-8-12
Abstract
In the article the problem of compliance to treatment is discussed considering pharmacodynamics of different classes of psychotropic drugs. Use of antipsychotics is associated with a high risk of non-compliance. Antipsychotics can inhibit the endogenous reward system and decreasing its tone reduce adherence to treatment. Both antidepressants and anxiolytics increase the tone of the reward system. But if for antidepressants an increase in adherence is associated with the activation of the reward system limited by related clinical effects, for anxiolytics high adherence to treatment is associated to the rapid development of specific effect and an indirect increase in the tone of the reward system with an increase general subjective satisfaction with treatment. The tolerance associated with the chronic use of benzodiazepine anxiolytics secondarily worsens the situation leading to the development of pathological addiction.
About the Authors
V. L. Kozlovskii
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Vladimir L. Kozlovskii
O. V. Lepik
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Olga V. Lepik
M. Yu. Popov
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Mikhail Yu. Popov
D. N. Kosterin
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Dmitriy N. Kosterin
References
1. Kozlovskii VL. Suppression of the punishment system and prospects of pharmacotherapeutical correction of addictions. Voprosy narkologii. 2014;1:111-120. (In Russ.).
2. Lapin I.P. Lichnost’ i lekarstvo: Vvednie v psihologiyu farmakoterapii. Spb.:Dean. 2001. (In Russ.).
3. Lutova NB. Compliance and psychopathological symptoms. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. 2012;3:59-65 (In Russ.).
4. Lutova NB, Petrovskaya IN, Vid VD. Illness insight and medication compliance in psychoses. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. 2014;1:10-15. (In Russ.).
5. Consoli SG. Reflections about non compliance. Ann Dermatol Venereol. 2012;139(1):28-32. doi: 10.1016/S0151-9638(12)70106-0. PMID: 22305284
6. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011;20;340(1):80-7. doi: 10.1016/j.mce.2011.02.017. Epub 2011 Feb 24. PMID: 21354264
7. Dragoni Divrak D. Reward System: A Guide For Wellness. Adv Mind Body Med. 2020;34(1):4-7. PMID: 32277748
8. Fields HL, Margolis EB. Understanding opioid reward.Trends Neurosci. 2015;38(4):217-25. doi: 10.1016/j.tins.2015.01.002. Epub 2015 Jan 29. PMID: 25637939
9. Gray R, T Wykes, K Gournay From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs. 2002;9(3):277-84.doi: 10.1046/j.1365-2850.2002.00474.x.
10. Greenberg T, Fournier JC, Stiffler R, Chase HW et al. Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. Mol Psychiatry. 2020;25(7):1526-1536. doi: 10.1038/s41380-019-0490-5. Epub 2019 Aug 28.PMID: 31462766
11. Juckel G. Inhibition of the reward system by antipsychotic treatment. Dialogues Clin Neurosci. 2016;18(1):109-14. doi: 10.31887/DCNS.2016.18.1/gjuckel. PMID: 27069385
12. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-90. doi: 10.1016/j.pnpbp.2003.09.004. PMID: 14642968
13. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59:29-53. doi: 10.1146/annurev.psych.59.103006.093548. PMID: 18154498
14. Koob GF. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction. Psychopharmacology (Berl). 2017;234(9-10):1315-1332. doi: 10.1007/s00213-016-4484-6. Epub 2017 Jan 3.PMID: 28050629
15. Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr Opin Neurobiol. 2013;23(4):559-63. doi: 10.1016/j.conb.2013.03.011. Epub 2013 Apr 27.PMID: 23628232
16. Liu JF, Li JX. Drug addiction: a curable mental disorder? Acta Pharmacol Sin. 2018;39(12):1823-1829. doi: 10.1038/s41401-018-0180-x. Epub 2018 Oct 31. PMID: 30382181
17. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci. 2005;255(3):190-201. doi: 10.1007/s00406-005-0587-5. PMID: 15995903
18. O’Sullivan SJ, Schwaber JS. Similarities in alcohol and opioid withdrawal syndromes suggest common negative reinforcement mechanisms involving the interoceptive antireward pathway.Neurosci Biobehav Rev. 2021;125:355-364. doi: 10.1016/j.neubiorev.2021.02.033. Epub 2021 Feb 26.PMID: 33647322
19. Playle JF, P Keeley Non-compliance and professional power. J Adv Nurs. 1998;27(2):304-11. doi: 10.1046/j.1365-2648.1998.00530.x.
20. Reddy M S Non-compliance in pharmacotherapy Indian J Psychol Med. 2012;34(2):107-9. doi: 10.4103/0253-7176.101762
21. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27. doi: 10.1152/jn.1998.80.1.1. PMID: 9658025
22. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M, Claes S. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013;73(7):639-45. doi: 10.1016/j.biopsych.2012.10.014. Epub 2012 Dec 8. PMID: 23228328
23. Wright EC. Non-compliance--or how many aunts has Matilda? Lancet. 1993 Oct 9;342(8876):909-13. doi: 10.1016/0140-6736(93)91951-h. PMID: 8105172
Review
For citations:
Kozlovskii V.L., Lepik O.V., Popov M.Yu., Kosterin D.N. The role of pharmacogenic factor in the modulation of compliance to treatment. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2022;56(3):8-12. (In Russ.) https://doi.org/10.31363/2313-7053-2022-56-3-8-12
Views:
338
Email this article 